144 results about "Serotype" patented technology

The invention relates to the technical field of molecular biology, in particular to an avian adenovirus serum type 4 colloidal gold test strip based on a monoclonal antibody and application of the test strip. According to the invention, two monoclonal antibodies (6B3 and 8G11) aiming at FAdV4 penton protein are successfully prepared through a hybridoma technology, and both the monoclonal antibodies show high titer and strong serotype specificity. Specific analysis proves that the two monoclonal antibodies can recognize 12 FAdV4 isolates from different sources, and do not have cross reaction with other FAdV serotypes or common poultry pathogens. According to the invention, through systematic optimization of key parameters, the detection sensitivity of the test strip is 7.81 * 10 < 4 > TCID50 / 0.1 mL, and the detection time is only 15 minutes. Clinical sample verification shows that compared with an ELISA method, the total coincidence rate is 98.6%.

According to various aspects of this disclosure, the present disclosure relates to methods for reducing kidney inflammation, reducing kidney fibrosis, reducing oxidative stress in the kidney, preventing or reducing the likelihood of chronic kidney disease (CKD), treating or preventing acute kidney injury (AKI) or treating a kidney disease in a subject in need thereof comprising administering, e.g., intramuscularly, to the subject a recombinant adeno-associated virus (rAAV) vector, wherein the rAAV vector comprises a vector genome comprising a nucleotide sequence encoding a Fibroblast growth factor 21 (FGF21) or a functional fragment thereof and an AAV capsid (e.g., AAV1 serotype), optionally, wherein the subject does not suffer from diabetes.

The invention discloses a pasteurella phage PTP1APTYT15 as well as a composition, a kit and application of the pasteurella phage PTP1APTYT15, the pasteurella phage PTP1APTYT15 is preserved in Guangdong Microbial Culture Collection Center on September 10, 2025, the preservation number of the pasteurella phage PTP1APTYT15 is GDMCC NO: 66946-B1, and the pasteurella phage PTP1APTYT15 is classified and named as Pasteurella phage PTP1APTYT15. The pasteurella phage PTP1APTYT15 provided by the invention has the characteristics of high temperature resistance and alkali resistance, and can be used for cracking pasteurella of various serotypes. In addition, the bacteriophage is high in proliferation efficiency and high in splitting capacity, has no adverse effect on human or animal health, and has good biological safety.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

This invention belongs to the field of molecular biology detection technology, specifically relating to a primer and probe combination for detecting avian Salmonella based on the RAA-LFD method and its application, particularly to a primer and probe combination for detecting three avian serotypes of Salmonella: Salmonella pullorum, Salmonella enteritidis, and Salmonella typhimurium, based on the RAA-LFD method and its application. This invention designs different types of probes and primers targeting the genes of serotypes SP, SE, and STM of Salmonella. Using the primer and probe combination of this invention, rapid, sensitive, and specific detection of Salmonella serotypes and the three avian Salmonella serotypes SP, SE, and STM can be achieved, greatly shortening the detection cycle of avian salmonellosis and improving the detection efficiency and accuracy of avian salmonellosis.

The invention discloses a porcine circovirus type 2 and haemophilus parasuis bivalent inactivated vaccine and a preparation method thereof. According to the invention, a porcine circovirus strain, a haemophilus parasuis serum type 4 strain and a haemophilus parasuis serum type 5 strain which are epidemic in situ are respectively separated and obtained, and the microbial preservation numbers of the porcine circovirus strain, the haemophilus parasuis serum type 4 strain and the haemophilus parasuis serum type 5 strain are respectively CGMCC (China General Microbiological Culture Collection Center) No.47094, CGMCC No.46698 and The separated strain or bacterial strain is prepared into a bivalent inactivated vaccine, and lentinan is added in the vaccine preparation process to enhance the immune effect; a safety evaluation result shows that local or whole-body adverse reaction caused by the bivalent vaccine does not occur, so that the safety of the bivalent vaccine is good; the immune efficacy evaluation result of the bivalent vaccine shows that the bivalent vaccine can provide complete protection for animals aiming at the in-situ epidemic porcine circovirus, haemophilus parasuis serotype 4 and haemophilus parasuis serotype 5, and has good immune protection efficacy.

This invention discloses a method for preparing a bivalent inactivated vaccine against bovine Pasteurella multocida type A and B and hemolytic Mansicular disease, belonging to the field of vaccine technology. The invention involves isolating capsular serum Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease; separately expanding the culture of these bacteria, then inactivating and concentrating the bacterial suspensions, and resuspending them in PBS to prepare bacterial suspensions; and finally, mixing the Pasteurella multocida type A, Pasteurella multocida type B, and hemolytic Mansicular disease suspensions with aluminum hydroxide adjuvant to prepare the inactivated vaccine. This invention provides simultaneous prevention of two diseases—bovine fibrinous purulent pneumonia and bovine hemorrhagic septicemia—as well as bovine Mansicular disease through vaccine immunization. The vaccine demonstrates good safety, stable immunization efficacy, and a long duration of immunity.

The invention belongs to the technical field of molecular biology, and discloses a truncated outer membrane protein of klebsiella pneumoniae and application thereof. The invention provides an outer membrane protein Lol B of klebsiella pneumoniae, which can be used for immunizing to induce a protective antibody aiming at various serotypes of klebsiella pneumoniae and killing the klebsiella pneumoniae. Specifically, the outer membrane protein Lol B immune serum can efficiently kill Klebsiella pneumoniae, and when a mouse immunized by the outer membrane protein Lol B immune serum is attacked by K1, K2 and K6 serotype Klebsiella pneumoniae, the mouse can be completely protected to survive, and the trend of weight loss of the mouse is remarkably reduced. Therefore, the outer membrane protein Lol B provided by the invention has a clinical application value for preventing and treating klebsiella pneumoniae infection.

This invention relates to the packaging and screening of viral vectors, particularly to the packaging and screening of AAV mutants, specifically an adeno-associated virus mutant that efficiently infects HT-22 cells. By constructing a peptide mutant library of AAV9, a new AAV9 mutant with seven inserted amino acids was obtained through screening and verification. This mutant can effectively infect HT-22 cells at an MOI of 1E+5, achieving a higher infection rate than the natural AAV9 serotype at MOI=1E+5. The AAV9-HT01 mutant obtained after screening showed the best effect, with a significantly higher infection positivity rate compared to the control AAV9 serotype under the same MOI conditions. The fold increase was 4.4-fold as measured by luciferase (RLU) value detection. This effectively reduces the amount of AAV cells used for infection, saving experimental costs, and simultaneously makes it feasible to study the mechanisms of gene therapy for central nervous system diseases in HT-22 cells.

The invention discloses a cryptococcus capsular polysaccharide detection kit. The cryptococcus capsular polysaccharide detection kit comprises a biotin-labeled cryptococcus monoclonal antibody and an acridinium ester-labeled cryptococcus monoclonal antibody, wherein the biotin-labeled cryptococcus monoclonal antibody and the acridinium ester-labeled cryptococcus monoclonal antibody are coupled with streptavidin magnetic beads. According to the cryptococcus capsular polysaccharide detection kit disclosed by the invention, the biotin-labeled cryptococcus monoclonal antibody coupled with the streptavidin magnetic beads and the acridinium ester-labeled cryptococcus monoclonal antibody are matched, so that the cryptococcus capsular polysaccharide detection kit has relatively strong recognition capability on various serotypes of cryptococcus, and the antibodies do not interfere with one another; according to the cryptococcus capsular polysaccharide detection kit, the detection sensitivity and the detection accuracy can be greatly improved, the problem that a detection result is greatly influenced by subjective consciousness and is inaccurate due to the fact that an existing detection method only depends on visual inspection is solved, and the cryptococcus capsular polysaccharide detection kit is convenient to operate, facilitates automatic operation of an instrument and reduces manual errors.

The invention is directed to cocktails of different antibodies and methods of treating a patient. Antibodies of the collection are specifically reactive to different viral serotypes or species. Cocktails may comprise monoclonal antibodies with one or more having an extended half-life. For treating or preventing viral infections, cocktails may comprise antibodies against conserved regions of HA, NA and M proteins of influenza virus and / or conserved regions of S, M, E, P, N or NS proteins of coronavirus. Monoclonal antibody combinations enhance phagocytosis and killing of viruses by phagocytic cells, and enhance clearance of the infecting virus from the blood.

The invention belongs to the technical field of monoclonal antibodies, and particularly relates to a PPRV HN-targeted monoclonal antibody and application thereof. The PPRV HN-targeted monoclonal antibody is characterized by comprising a light chain and a heavy chain, and the amino acid sequence of a variable region of the light chain comprises QSIVHSSGNTY, KYS and FQGSHVPYT. And the amino acid sequences of the variable region of the heavy chain comprise GFNIKDYY, IDPENGYT and AELGRGSY. The monoclonal antibody provided by the invention provides a new effective tool and solution for veterinary detection, diagnosis, prevention and treatment of the PPRV serotype.

Provided is an RNA editing system activating a Wnt signaling pathway, relating to the field of gene editing. Provided is an RNA editing element, comprising an Axin1-targeting RNA fragment and an Axin2-targeting RNA fragment. A gRNA that targets both Axin1 and Axin2 is constructed, which, compared with gRNAs targeting Axin1 or Axin2 alone, can significantly up-regulate Wnt activity. An AAV6 vector is screened from three AAV vectors of different serotypes, and exhibits relatively high expression intensity and efficiency and high infection efficiency with respect to airway epithelial cells and alveolar epithelial cells while exhibiting very low infection efficiency with respect to immune cells and endothelial cells. The AAV vector is assembled with a Cre-LoxP recombinase system to together infect a host cell, thereby facilitating the measurement of Cas13d knockdown efficiency by means of fluorescent labeling.

This invention relates to the application of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 in the preparation of a kit for detecting avian adenovirus serotype 4 antibodies. The amino acid sequence of the avian adenovirus serotype 4 multi-epitope recombinant chimeric protein rcF2 is shown in SEQ ID NO.1. This invention utilizes the multi-epitope recombinant chimeric protein rcF2 to establish an indirect ELISA detection method and kit for detecting avian adenovirus serotype 4. This recombinant chimeric protein can be recognized by avian adenovirus serotype 4 positive sera, and the detection sensitivity of positive sera samples can reach 1:16000. It shows no cross-reactivity with antibodies against other pathogens, indicating that the ELISA detection method based on this multi-epitope recombinant chimeric protein rcF2 is simple to operate, enhances detection sensitivity, and has good specificity and repeatability.

The invention provides a 19F streptococcus pneumoniae invasiveness risk prediction method, and relates to the technical field of molecular biology. Wherein the evaluation marker combination comprises a translation genome, a cell synthesis genome and a ligand transport metabolism genome; the translation genome comprises rluB and rsmE; the cell synthetic genome comprises mscL and murI; and the ligand transport metabolism genome comprises czcD, site B, mtsC and pstS. The evaluation marker combination can accurately evaluate the invasive risk of serotype 19F streptococcus pneumoniae, and realizes molecular typing and risk prediction. The kit has high sensitivity and specificity, is suitable for high-throughput detection, and is helpful for clinical diagnosis and pathogenic mechanism research.

Form-specific cell based assays for the characterization of Clostridia botulinum neurotoxins and genetically modified cells utilized in such assays are described. Such assays and genetically modified cells can discriminate between complexed and non-complexed forms of botulinum neurotoxin having the same serotype, for example serotype E. Methods are also provided for generating and identifying cell lines that can be utilized in such cell based assays.

This disclosure relates to immunogenic compositions comprising attenuated and / or dead streptococcal bacterial strains, including modifications that reduce, decrease, or prevent the functional expression of LytC (or its homologues). Such compositions may be used in vaccine compositions. Immunogenic compositions and / or vaccine compositions may be used in methods for inducing an immune response to at least one target streptococcal species and / or its serotype, and / or for preventing or mitigating infections and / or diseases or conditions in a subject caused by at least one target streptococcal species and / or its serotype.

The invention discloses an efficient blood brain barrier crossing adeno-associated virus mutant and application, and relates to the technical field of biological medicine. A587Q588 in the amino acid of the AAV9 serotype capsid protein is replaced by a heterologous peptide; the heterologous peptide is a polypeptide consisting of any one of amino acid sequences in DGTIQAPFR (Databine Glycine Triphosphate Quantitative Amplified Polypeptide Receptor) or DGTTFTPPR ( The infection efficiency, mRNA (messenger ribonucleic acid) and protein expression of the SG302 and the SG303 on brain, spinal cord and thalamic neurons of a mouse are obviously higher than those of AAV9, and the infection capacity on the liver is obviously lower than that of the AAV9. The SG302 and the SG303 are serotype mutants with good specificity for a nervous system, the high infection efficiency can reduce the administration dosage, and the low hepatotrophy characteristic can improve the safety performance.

The invention relates to shigella flexneri as well as related serotype and application of a preparation of the shigella flexneri in preparation of anti-tumor immune activation and treatment medicines. The shigella flexneri and the preparation thereof disclosed by the invention can improve a tumor immune microenvironment by activating anti-tumor immune response of an organism so as to inhibit tumor growth, and are suitable for prevention and / or treatment of various tumors; the strain and the preparation thereof can be independently used and can also be combined with existing tumor therapies such as chemotherapy, radiotherapy and immunotherapy to synergistically enhance the anti-tumor curative effect; the invention provides a new microbial resource and strategy for tumor immunotherapy, and has an important clinical application prospect.

The application relates to a protective antigen of streptococcus suis disease and application thereof, and belongs to the technical field of biological vaccines. The amino acid sequence shown in SEQ ID No. 1 provided in the application is used as a protective antigen of streptococcus suis disease. The protective antigen is obtained by codon optimization of the nucleotide sequence shown in SEQ ID No. 2, construction of an expression vector and prokaryotic expression, and the protective antigen is verified to be capable of providing good immune cross-protection for type 2 and type 7 streptococcus suis infection in different ways. The application scheme has important significance for research on a general vaccine candidate antigen of multiple serotypes of streptococcus suis and scientific prevention and control of the disease.

The present invention relates to a dengue vaccine formulation comprising a tetravalent dengue virus composition comprising a live attenuated dengue virus serotype 1, a live attenuated dengue virus serotype 2, a live attenuated dengue virus serotype 3, and a live attenuated dengue virus serotype 4, at least one non-reducing disaccharide, at least one poloxamer, urea, at least one amino acid having a positively charged side chain at neutral pH, tromethamine, and human serum albumin.

Described herein are systems and methods that may be used to differentially detect viral serotype specific nucleic acid. For example, these systems may comprise multiple DNA-nanostructures, capture oligonucleotides and protector oligonucleotides, wherein each DNA-nanostructure and its associated capture oligonucleotide and protector oligonucleotide are specific for a unique viral type or serotype.

A modified vector of adenovirus-associated virus serotype 8 (AAV-8) for gene targeting and expression is provided, wherein the modified vector includes serotype coat amino acid sequence, insertion site and insertion amino acid sequence. A 10-amino acid sequence set forth in SEQ ID NO.3 is inserted between amino acids at positions 590 and 591 that are set forth in SEQ ID NO.2 of the AAV-8 serotype coat protein: LARGDSTKSA, wherein amino acids at positions 1, 2 and 10 are protective amino acids, and amino acids at positions 3 to 9 are screened amino acid sequences. In addition, the present invention also discloses construction method and application of the modified vector are also provided.

The present invention provides a recombinant oncolytic adenovirus (Ad) comprising, as a backbone, an Ad serotype other than adenovirus serotype 5 (Ad serotype 5), which achieves a high viral yield and is capable of exhibiting a sufficient anti-tumor effect. Also provided is a pharmaceutical composition comprising the recombinant oncolytic Ad as an active ingredient. The recombinant oncolytic Ad is characterized in that: part or all of the E1 gene of Ad serotype 5 is incorporated into the E1 region of the Ad serotype genome other than Ad serotype 5; and a portion or all of the E4 gene of Ad serotype 5 is incorporated into the E4 region of the Ad serotype genome other than Ad serotype 5.

The invention provides a universal baculovirus transfer vector and application thereof. The universal baculovirus transfer vector comprises the following elements: (a) a 3CD protease coding gene containing Q184L mutation; (b) a baculovirus homologous repeat region enhancer hr1; (c) a baculovirus late expression factor lev5 gene and an expression regulatory element thereof; (d) a polh-pSel promoter used for driving the expression of the P1 protein; (e) a target serotype enterovirus P1 protein; wherein the elements (a)-(d) constitute a general core skeleton, and the element (e) allows insertion or replacement of a specific P1 protein gene. The 3CD stability is remarkably enhanced, the VLP yield and the assembling efficiency are greatly improved, the method has outstanding universality, and an efficient technical platform is provided for development of broad-spectrum enterovirus vaccines.

The invention relates to the technical field of gene engineering, and particularly discloses a serum type 5 haemophilus parasuis attenuated vaccine strain without antibody polygene deletion as well as a construction method and application of the serum type 5 haemophilus parasuis attenuated vaccine strain. According to the invention, crp, cpxAR and OmpP2 genes related to toxicity are deleted from a clinical isolated strain of a haemophilus parasuis serum type 5 virulent strain HN1570 by means of molecular biology to obtain a non-resistant polygene deleted strain HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR, and the deleted strain is preserved; tests find that the attenuated live vaccine prepared by using the HPS5deltaOmpP2 deltacrp deltacpxAR strain haemophilus parasuis as a strain antigen not only has 100% protection rate on infection of type 5, but also has better cross protection force on infection of other serotype haemophilus parasuis and haemophilus parasuis incapable of being classified, and a good immune protection effect can be achieved by using a small immunization amount; the result shows that the haemophilus parasuis HPS5 [delta] OmpP2 [delta] crp [delta] cpxAR strain has good immunogenicity; the vaccine is simple in preparation process, free of resistance genes, free of toxic and side effects, good in safety, long in immune period and good in immune effect, and can be used for industrial production.

The present invention relates to a recombinant protein comprising one or more fragments of the surface protein A (PspA) of the pneumococcal, and an adenylate cyclase (CyaA) from the genus Bordetella, in particular Bordetella pertussis, in which the fragments of the PspA are selected from the group consisting of clades 1 to 4, or a combination of two or more thereof. Furthermore, the present invention relates to an expression cassette comprising a DNA sequence encoding said recombinant protein, in particular a DNA sequence selected from the nucleotide sequences represented by SEQ ID NO: 12 to 18 and a degenerate sequence thereof, which respectively encode the recombinant protein represented by SEQ ID NO: 5 to 11. In addition, immunogenic compositions comprising the recombinant protein or the expression cassette and further pharmaceutically acceptable carriers and / or adjuvants are disclosed. Finally, the present invention relates to the use of said recombinant protein, said expression cassette or said immunogenic composition for the preparation of a vaccine for the prevention of infection by Streptococcus pneumoniae wherein said vaccine provides broad spectrum protection against different pneumococcal isolates regardless of serotypes.

The present disclosure provides methods and compositions to develop AAV capsids with a desired characteristic compared to a natural AAV serotype. These capsids are useful, for example, for the delivery of genome engineering molecules and gene therapy molecules for the treatment of a subject in need thereof.

The invention discloses a group A streptococcus mRNA (messenger Ribonucleic Acid) vaccine and application thereof, and relates to the technical field of biological medicines, in particular to the group A streptococcus mRNA vaccine and application thereof. The mRNA for coding the group A streptococcus antigen contains an open reading frame; the nucleotide sequence of the coding open reading frame is M12 <-N > + M1 <-N > + M4 <-N >, and is as shown in SEQ ID NO. 1; the antigen sequence of the group A streptococcus mRNA vaccine has no homology with human tissue protein through blastp comparison; the mRNA vaccine has strong immunogenicity, can effectively inhibit three GAS serotypes, and covers main GAS epidemic strains in China at present; the mRNA vaccine has the advantages of high efficiency, broad spectrum, high safety and simplicity and convenience in use, and is easy to popularize and use.